Abstract
Molecular therapy is emerging as a potential strategy for the treatment of cardiovascular diseases such as restenosis after angioplasty, vascular bypass graft occlusion, and transplant coronary vasculopathy, for which no effective therapy is known. One strategy for combating disease processes has been to target the transcriptional process. Two approaches have been used to accomplish this. One is the use of antisense RNA that is complimentary to the mRNA of interest. The second approach is the use of ribozymes, a unique class of RNA molecules that not only store information but also possess catalytic activity. Ribozymes are known to catalytically cleave specific target RNA, leading to their degradation, whereas antisense molecules inhibit translation by binding to mRNA sequences on a stoichiometric basis. In theory, ribozymes would be the more effective means of inhibiting expression of a target gene. The application of DNA technology such as the antisense strategy to regulate the transcription of disease-related genes in vivo has important therapeutic potential. Transfection of cis-element double-stranded (ds) oligodeoxynucleotides (ODN) (decoy) has been reported as a powerful tool in a new class of anti-gene strategies for gene therapy. Transfection of decoy ODN will result in attenuation of authentic cis-trans interaction, leading to the removal of trans-factors from the endogenous cis-elements, with subsequent modulation of gene expression. This decoy ODN strategy is not only a novel strategy for gene therapy as an anti-gene strategy, but is also a powerful tool for the study of endogenous gene regulation in vivo as well as in vitro. In this review, we focus on the future potential of decoy ODN-based therapy.
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Preview
Unable to display preview. Download preview PDF.
References
Abe T, Takai K, Nakada S, Yokota T, Takaku H (1998) Specific inhibition of influenza virus RNA polymerase and nucleoprotein gene expression by circular dumbbell RNA/DNA chimeric oligonucleotides containing antisense phosphodiester oligonucleotides. FEBS Lett 425:91–96
Ahn JD, Morishita R, Kaneda Y, Kim HS, Chang YC, Lee KU, Park JY, Lee HW, Kim YH, Lee IK (2002a) 2F decoy oligodeoxynucleotides inhibit in vitro vascular smooth muscle cell proliferation and in vivo neointimal hyperplasia. Gene Ther 9:1682–1692
Ahn JD, Morishita R, Kaneda Y, Lee SJ, Kwon KY, Choi SY, Lee KU, Park JY, Moon IJ, Park JG, Yoshizumi M, Ouchi Y, Lee IK (2002b) Inhibitory effects of novel AP-1 decoy oligodeoxynucleotides on vascular smooth muscle cell proliferation in vitro and neointimal formation in vivo. Circ Res 90:1325–1332
Azuma H, Tomita N, Kaneda Y, Koike H, Ogihara T, Katsuoka Y, Morishita R (2003) Transfection of NFκB decoy oligodeoxynucleotides using efficient ultrasound-mediated gene transfer into donor kidneys prolonged survival of rat renal allografts. Gene Ther 10:415–425
Bahner I, Kearns K, Hao QL, Smogorzewska EM, Kohn DB(1996) Transduction of human CD34+ hematopoietic progenitor cells by a retroviral vector expressing an RRE decoy inhibits human immunodeficiency virus type 1 replication in myelomonocytic cells produced in long-term culture. J Virol 70:4352–4360
Burgess TL, Fisher EF, Ross SL, Bready JV, Qian YX, Bayewitch LA, Cohen AM, Herrera CJ, Hu SS, Kramer TB, Lott FD, Martin FH, Pierce GF, Simonet L, Farrell CL (1995) The antiproliferative activity of c-myb and c-myc antisense oligonucleotides in smooth muscle cells is caused by a nonantisense mechanism. Proc Natl Acad Sci USA 92:4051–4055
Chu BCF, Orgal L (1992) The stability of different forms of double-stranded decoy DNA in serum and nuclear extracts. Nucleic Acids Res 20:5857–5858
Cornish KG, Iversen P, Smith L, Arneson M, Bayever E (1993) Cardiovascular effects of a phosphorothioate oligonucleotide with sequence antisense to p53 in the conscious rhesus monkey. Pharmacol Commun 3:239
Crooke ST. Progress in antisense therapeutics (1995) Hematol Pathol 9:59–72
Gibbons GH, Dzau VJ (1994) The emerging concept of vascular remodeling. N Engl J Med 330:1431–1438
Gibson I (1996) Antisense approaches to the gene therapy of cancer — ‘Recnac’. Cancer Metastasis Rev 15:287–299
Henry SP, Bolte H, Auletta C, Kornbrust DJ (1997a) Evaluation of the toxicity of ISIS 2302, a phosphorothioate oligonucleotide, in a four-week study in cynomolgus monkeys. Toxicology 120:145–155
Henry SP, Giclas PC, Leeds J, Pangburn M, Auletta C, Levin AA, Kornbrust DJ (1997b) Activation of the alternative pathway of complement by a phosphorothioate oligonucleotide: potential mechanism of action. J Pharmacol Exp Ther 281:810–816
Kaneda Y, Nakajima T, Nishikawa T, Yamamoto S, Ikegami H, Suzuki N, Nakamura H, Morishita R, Kotani T (2002) Hemagglutinating Virus of Japan (HVJ) envelope vector as a versatile gene delivery system. Mol Ther 6:219–226
Kawamura I, Morishita R, Tsujimoto S, Manda T, Tomoi M, Tomita N, Goto T, Ogihara T, Kaneda Y (2001) Intravenous injection of oligodeoxynucleotides to the NF-kappaB binding site inhibits hepatic metastasis of M5076 reticulosarcoma in mice. Gene Ther 8:905–912
Khaled Z, Benimetskaya L, Zeltser R, Khan T, Sharma HW, Narayanan R, Stein CA (1996) Multiple mechanisms may contribute to the cellular anti-adhesive effects of phosphorothioate oligodeoxynucleotides. Nucl Acids Res 24:737–745
Kiehntopf M, Esquivel EL, Brach MA, Herrmann F (1995) Clinical applications of ribozymes. Lancet 345:1027–1031
Kutryk MJ, Foley DP, van den Brand M, Hamburger IN, van der Giessen WJ, de Feyter PJ, Bruining N, Sabate M, Serruys PW (2002) Local intracoronary administration of antisense oligonucleotide against c-myc for the prevention of in-stentrestenos is: results of the randomized investigation by the Thoraxcenter of antisense DNA using local delivery and IVUS after coronary stenting (ITALICS) trial. J Am Coll Cardiol 39:281–287
Lee SW, Gallardo HF, Gaspar O, Smith C, Gilboa E (1995) Inhibition of HIV-1 in CEM cells by a potent TAR decoy. Gene Ther 2:377–384
Maeshima Y, Kashihara N, Yasuda T, Sugiyama H, Sekikawa T, Okamoto K, Kanao K, Watanabe Y, Kanwar YS, Makino H (1998) Inhibition of mesangial cell proliferation by E2F decoy oligodeoxynucleotide in vitro and in vivo. J Clin Invest 101:2589–2597
Mann MJ, Whittemore AD, Donaldson MC, Belkin M, Conte MS, Polak JF, Orav EJ, Ehsan A, Dell’Acqua G, Dzau VJ (1999) Ex-vivo gene therapy of human vascular bypass grafts with E2F decoy: the PREVENT single-centre, randomised, controlled trial. Lancet 354:1493–1498
Morishita R, Gibbons GH, Ellison KE, Nakajima M, Zhang L, Kaneda Y, Ogihara T, Dzau VJ (1993) Single intraluminal delivery of antisense cdc 2 kinase and PCNA oligonucleotides results in chronic inhibition of neointimal hyperplasia. Proc Natl Acad Sci USA 90:8474–8479
Morishita R, Gibbons GH, Ellison KE, Nakajima M, Leyen HVL, Zhang L, Kaneda Y, Ogihara T, Dzau VJ (1994a) Intimal hyperplasia after vascular injury is inhibited by anti sense cdk 2 kinase oligonucleotides. J Clin Invest 93:1458–1464
Morishita R, Gibbons GH, Kaneda Y, Ogihara T, Dzau VJ (1994b) Pharmacokinetics of antisense oligonucleotides (cyclin B1 and cdc 2 kinase) in the vessel wall: enhanced therapeutic utility for restenosis by HVJ-liposome method. Gene 149:13–19
Morishita R, Gibbons GH, Horiuchi M, Ellison KE, Nakajima M, Zhang L, Kaneda Y, Ogihara T, Dzau VJ (1995) A novel molecular strategy using cis element ‘decoy’ of E2F binding site inhibits smooth muscle proliferation in vivo. Proc Natl Acad Sci USA 92:5855–5859
Morishita R, Sugimoto T, Aoki M, Kida I, Tomita N, Moriguchi A, Maeda K, Sawa Y, Kaneda Y, Higaki J, Ogihara T (1997) In vivo transfection of cis element ‘decoy’ against NFκB binding site prevented myocardial infarction as gene therapy. Nat Med 3:894–899
Morishita R, Higaki J, Tomita N, Ogihara T (1998) Application of transcription factor ‘decoy’ strategy as means of gene therapy and study of gene expression in cardiovascular disease. Circ Res 82:1023–1028
Nakamura H, Aoki M, Tarnai K, Oishi M, Ogihara T, Kaneda Y, Morishita R (2002) Prevention and regression of atopic dermatitis by ointment containing NF-kB decoy oligodeoxynucleotides in NC/Nga atopic mouse model. Gene Ther 9:1221–1229
Nakamura T, Morishita R, Asai T, Tsuboniwa N, Aoki M, Sakonjo H, Yamasaki K, Hashiya N, Kaneda Y, Ogihara T (2002) Molecular strategy using cis-element ‘decoy’ of E2F binding site inhibits neointimal formation in porcine balloon-injured coronary artery model. Gene Ther 9:488–494
Roque F, Mon G, Belardi J, Rodriguez A, Grinfeld L, Long R, Grossman S, Malcolm A, Zon G, Ormont ML, Fischman DL, Shi Y, Zalewski A (2001) Safety of intra coronary administration of c-myc antisense oligomers after percutaneous transluminal coronary angioplasty (PTCA). Antisense Nucleic Acid Drug Dev 2:99–106
Sawa Y, Morishita R, Suzuki K, Kagisaki K, Kaneda Y, Maeda K, Kadoba K, Matsuda H (1997) A novel strategy for myocardial protection using in vivo transfection of cis element ‘decoy’ against NFκB binding site: evidence for a role of NFκB in ischemicreperfusion injury. Circulation 965:280–285
Shi Y, Fard A, Galeo A, Hutchinson HG, Vermami P, Dodge GR, Hall DJ, Shaheen F, Zalewski A (1994) Transcatheter delivery of c-myc antisense oligomers reduces neointimal formation in a porcine model of coronary artery balloon injury. Circulation 90:944–951
Srinivasan SK, Iversen P (1995) Review of in vivo pharmacokinetics and toxicology of phosphorothioate oligonucleotides. J Clin Lab Anal 9:129–137
Stein CA, Cohen JS (1988) Oligodeoxynucleotides as inhibitors of gene expression: a review. Cancer Res 48:2659–2668
Sullenger BA, Gallardo HF, Ungers GE, Giboa E (1990) Overexpression of TAR sequence renders cells resistant to human immunodeficiency virus replication. Cell 63:601–608
Suzuki J, Morishita R, Amano J, Kaneda Y, Isobe M (2000) Decoy against nuclear factorkappa B attenuates myocardial cell infiltration and arterial neointimal formation in murine cardiac allografts. Gene Ther 7:1847–1852
Tomita N, Morishita R, Tomita S, Gibbons GH, Zhang L, Horiuchi M, Kaneda Y, Higaki J, Ogihara T, Dzau VJ (2000b) Transcription factor decoy for NFkB inhibits TNF-α-induced cytokine and adhesion molecule expression in vivo. Gene Ther 7:1326–1332
Tomita N, Morishita R, Lan HY, Yamamoto K, Hashizume M, Notakae M, Toyosawa K, Fujitani B, Mu W, Nikolic-Paterson DJ, Atkins RC, Kaneda Y, Higaki J, Ogihara T (2002a) In vivo administration of a nuclear transcription factor-κB decoy suppresses experimental crescentic glomerulonephritis. J Am Soc Nephrol 11:1244–1252
Tomita N, Morishita R, Tomita S, Kaneda Y, Higaki J, Ogihara T, Horiuchi M (2001) Inhibition of TNF-alpha, induced cytokine and adhesion molecule expression in glomerular cells in vitro and in vivo by transcription factor decoy for NFκB. Exp Nephrol 9:181–190
Tomita T, Takeuchi E, Tomita N, Morishita R, Kaneko M, Yamamoto K, Nakase T, Seki H, Kato K, Kaneda Y, Ochi T (1999) Suppressed severity of collagen-induced arthritis by in vivo tran sfection of nuclear factor kappaB decoy oligodeoxynucleotides as a gene therapy. Arthritis Rheum 42:2532–2542
Tomita T, Takano H, Tomita N, Morishita R, Kaneko M, Shi K, Takahi K, Nakase T, Kaneda Y, Yoshikawa H, Ochi T (2000) Transcription factor decoy for nuclear factor kappaB inh ibits cytokine and adhesion molecule expressions in synovial cells derived from rheumatoid arthritis. Rheumatology 39:749–757
Yamasaki K, Asai T, Shimizu M, Aoki M, Hashiya N, Sakonjo H, Makino H, Kaneda Y, Ogihara T, Morishita R (2003) Inhib ition of NFKB activation using cis-element ‘decoy’ of NFKB binding site reduces neointimal formation in porcine balloon-injured coronary artery model. Gene Ther 10:356–364
Yokoseki O, Suzuki J, Kitabayashi H, Watanabe N, Wada Y, Aoki M, Morishita R, Kaneda Y, Ogihara T, Futamatsu H, Kobayashi Y, Isobe M (2001) Cis element decoy against nuclear factor-kappaB attenuates development of experimental autoimmune myocarditis in rats. Circ Res 89:899–906
Yoshimura S, Morishita R, Hayashi K, Yamamoto K, Nakagami H, Kaneda Y, Sakai N, Ogihara T (2001) Inhibition of intimal hyperplasia after balloon injury in rat carotid artery model using cis-element ‘decoy’ of nuclear factor-kB binding site as a novel molecular strategy. Gene Ther 8:1635–1642
Author information
Authors and Affiliations
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2004 Springer-Verlag
About this chapter
Cite this chapter
Morishita, R., Tomita, N., Kaneda, Y., Ogihara, T. (2004). Potential of Transcription Factor Decoy Oligonucleotides as Therapeutic Approach. In: Gossen, M., Kaufmann, J., Triezenberg, S.J. (eds) Transcription Factors. Handbook of Experimental Pharmacology, vol 166. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-642-18932-6_14
Download citation
DOI: https://doi.org/10.1007/978-3-642-18932-6_14
Publisher Name: Springer, Berlin, Heidelberg
Print ISBN: 978-3-642-62361-5
Online ISBN: 978-3-642-18932-6
eBook Packages: Springer Book Archive